anti-NKG2A Monoclonal Antibody

Product Description

anti-NKG2A Monoclonal Antibody
Catalog number: B2015087
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 10 µl
Molecular Weight or Concentration: N/A
Supplied as: Solution
Applications: molecular tool for various biochemical applications
Storage: 2-8°C
Keywords: CD antigen CD159a;CD159 antigen-like family member A;CD159A;C-lectin type II protein;killer cell lectin-like receptor subfamily C, member 1;natural killer cell lectin;natural killer group protein 2
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells Cell. 2018 Dec 13;175(7):1731-1743.e13.
2: Taylor BC, Sun X, Gonzalez-Ericsson PI, Sanchez V, Sanders ME, Wescott EC, Opalenik SR, Hanna A, Chou ST, Van Kaer L, Gomez H, Isaacs C, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Pietenpol JA, Balko JM. NKG2A is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple Negative Breast Cancer Cancer Discov. 2023 Oct 4.
3: Kamiya T, Seow SV, Wong D, Robinson M, Campana D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells J Clin Invest. 2019 Mar 12;129(5):2094-2106.
4: Melero I, Ochoa MC, Molina C, Sanchez-Gregorio S, Garasa S, Luri-Rey C, Hervas-Stubbs S, Casares N, Elizalde E, Gomis G, Cirella A, Berraondo P, Teijeira A, Alvarez M. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies EMBO Mol Med. 2023 Nov 8;15(11):e17804.
5: Jiang H, Yu D, Yang P, Guo R, Kong M, Gao Y, Yu X, Lu X, Fan X. Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing Clin Transl Med. 2022 Feb;12(2):e730.
6: Courau T, Bonnereau J, Chicoteau J, Bottois H, Remark R, Assante Miranda L, Toubert A, Blery M, Aparicio T, Allez M, Le Bourhis L. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment J Immunother Cancer. 2019 Mar 14;7(1):74.
7: Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer 34851
8: Cascone T, Kar G, Spicer JD, García-Campelo R, Weder W, Daniel DB, Spigel DR, Hussein M, Mazieres J, Oliveira J, Yau EH, Spira AI, Anagnostou V, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, Tan TH, Surace M, Rodriguez-Canales J, Gopalakrishnan V, Sellman BR, Grenga I, Soo-Hoo Y, Kumar R, McGrath L, Forde PM. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial Cancer Discov. 2023 Nov 1;13(11):2394-2411.
9: Mingari MC, Pietra G, Moretta L. Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board 32942
10: Ruggeri L, Urbani E, André P, Mancusi A, Tosti A, Topini F, Bléry M, Animobono L, Romagné F, Wagtmann N, Velardi A. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells 30348

Products Related to anti-NKG2A Monoclonal Antibody can be found at Antibodies